Completed PHASE1 INTERVENTIONAL 2-arm NCT04906629

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (Boost-EBOV)

Phase Ib, Placebo-controlled Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 Followed by Electroporation as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine

Sponsor: Defense Advanced Research Projects Agency

Conditions Ebola Virus Disease

Interventions INO-4201 Placebo

Updated 4 times since 2021 Last updated: May 22, 2022 Started: Sep 1, 2021 Primary completion: Jan 5, 2022 Completion: May 11, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Ebola Virus Disease and is currently completed. Defense Advanced Research Projects Agency leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jun 2021 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Defense Advanced Research Projects Agency
Global Urgent and Advanced Research and Development (GuardRX)
Inovio Pharmaceuticals
University of Geneva, Switzerland

Data source: University of Geneva, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland